Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of “Moderate Buy” by Analysts

Nurix Therapeutics, Inc. (NASDAQ:NRIX) has earned an average rating of “Moderate Buy” from the nineteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, thirteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $26.8750.

A number of research analysts have recently weighed in on NRIX shares. Oppenheimer lowered their price target on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating on the stock in a report on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Wednesday, October 8th. Baird R W upgraded Nurix Therapeutics to a “strong-buy” rating in a report on Tuesday, August 26th. Stifel Nicolaus set a $33.00 price target on shares of Nurix Therapeutics in a report on Friday, October 10th. Finally, Piper Sandler dropped their price objective on shares of Nurix Therapeutics from $35.00 to $32.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX opened at $16.91 on Tuesday. The firm has a 50 day simple moving average of $11.88 and a 200 day simple moving average of $11.19. Nurix Therapeutics has a 52 week low of $8.18 and a 52 week high of $23.00. The company has a market cap of $1.30 billion, a PE ratio of -5.69 and a beta of 1.87.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, October 9th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.19). Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%.The firm had revenue of $7.89 million for the quarter, compared to analysts’ expectations of $16.06 million. On average, equities analysts predict that Nurix Therapeutics will post -2.99 earnings per share for the current year.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 4,087 shares of the company’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $12.80, for a total value of $52,313.60. Following the transaction, the insider directly owned 76,751 shares of the company’s stock, valued at $982,412.80. This represents a 5.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Houte Hans Van sold 6,284 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $12.56, for a total value of $78,927.04. Following the sale, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at $472,155.52. This trade represents a 14.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 13,501 shares of company stock worth $171,305 over the last ninety days. 7.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Nurix Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wexford Capital LP acquired a new stake in Nurix Therapeutics in the third quarter valued at approximately $41,000. Tower Research Capital LLC TRC raised its holdings in shares of Nurix Therapeutics by 118.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after purchasing an additional 3,475 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new position in shares of Nurix Therapeutics during the 3rd quarter valued at $100,000. 49 Wealth Management LLC acquired a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at $108,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Nurix Therapeutics in the third quarter worth $109,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.